Novo Holdings’ proposed $16.5bn acquisition of one of the largest healthcare CDMOs, Catalent, is being delayed due to the Federal Trade Commission (FTC) requiring further information. The Danish company had planned to acquire Catalent’s three sterile injectable drug sites, potentially boosting their production capacity. However, the deal, which was already resubmitted for FTC approval once, is facing scrutiny due to antitrust concerns.
